Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

TISLELIZUMAB-JSGR: 50 Adverse Event Reports & Safety Profile

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now
50
Total FAERS Reports
11 (22.0%)
Deaths Reported
18
Hospitalizations
50
As Primary/Secondary Suspect
1
Life-Threatening
1
Disabilities
Prescription
Status

FDA Application: 761232 ·

First Report: 20220201 · Latest Report: 20250703

What Are the Most Common TISLELIZUMAB-JSGR Side Effects?

#1 Most Reported
Disease progression
15 reports (30.0%)
#2 Most Reported
Off label use
9 reports (18.0%)
#3 Most Reported
Pneumonia
8 reports (16.0%)

All TISLELIZUMAB-JSGR Side Effects by Frequency

Side Effect Reports % of Total Deaths Hosp.
Disease progression 15 30.0% 2 0
Off label use 9 18.0% 2 1
Anaemia 8 16.0% 1 1
Pneumonia 8 16.0% 2 7
Lymphadenopathy 7 14.0% 0 0
Thrombocytopenia 7 14.0% 0 0
Infusion related reaction 6 12.0% 0 6
Pyrexia 6 12.0% 0 5
Death 5 10.0% 5 0

Who Reports TISLELIZUMAB-JSGR Side Effects? Age & Gender Data

Gender: 53.5% female, 46.5% male. Average age: 63.3 years. Most reports from: GB. View detailed demographics →

Is TISLELIZUMAB-JSGR Getting Safer? Reports by Year

YearReportsDeathsHosp.
2022 3 0 0
2024 6 0 6
2025 3 2 3

View full timeline →

What Is TISLELIZUMAB-JSGR Used For?

IndicationReports
Oesophageal adenocarcinoma 13
Oesophageal squamous cell carcinoma 11
Product used for unknown indication 10
Richter's syndrome 9
Chronic lymphocytic leukaemia 8
Diffuse large b-cell lymphoma 8
Gastrooesophageal reflux disease 6
Prophylaxis 6

Official FDA Label for TISLELIZUMAB-JSGR

Official prescribing information from the FDA-approved drug label.